Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test

药物遗传学 全基因组关联研究 遗传关联 考试(生物学) 医学 联想(心理学) 计算生物学 生物信息学 遗传学 生物 基因型 心理学 单核苷酸多态性 基因 生态学 心理治疗师
作者
Benoît Delabays,Katerina Trajanoska,Joshua Walonoski,Vincent Mooser
出处
期刊:Pharmacological Reviews [American Society for Pharmacology and Experimental Therapeutics]
卷期号:76 (5): 791-827 被引量:3
标识
DOI:10.1124/pharmrev.123.000750
摘要

Recent breakthroughs in human genetics and in information technologies have markedly expanded our understanding at the molecular level of the response to drugs, i.e., pharmacogenetics (PGx), across therapy areas. This review is restricted to PGx for cardiovascular (CV) drugs. First, we examined the PGx information in the labels approved by regulatory agencies in Europe, Japan, and North America and related recommendations from expert panels. Out of 221 marketed CV drugs, 36 had PGx information in their labels approved by one or more agencies. The level of annotations and recommendations varied markedly between agencies and expert panels. Clopidogrel is the only CV drug with consistent PGx recommendation (i.e., "actionable"). This situation prompted us to dissect the steps from discovery of a PGx association to clinical translation. We found 101 genome-wide association studies that investigated the response to CV drugs or drug classes. These studies reported significant associations for 48 PGx traits mapping to 306 genes. Six of these 306 genes are mentioned in the corresponding PGx labels or recommendations for CV drugs. Genomic analyses also highlighted the wide between-population differences in risk allele frequencies and the individual load of actionable PGx variants. Given the high attrition rate and the long road to clinical translation, additional work is warranted to identify and validate PGx variants for more CV drugs across diverse populations and to demonstrate the utility of PGx testing. To that end, pre-emptive PGx combining genomic profiling with electronic medical records opens unprecedented opportunities to improve healthcare, for CV diseases and beyond.

Significance Statement

Despite spectacular breakthroughs in human molecular genetics and information technologies, consistent evidence supporting PGx testing in the cardiovascular area is limited to a few drugs. Additional work is warranted to discover and validate new PGx markers and demonstrate their utility. Pre-emptive PGx combining genomic profiling with electronic medical records opens unprecedented opportunities to improve healthcare, for CV diseases and beyond.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ce发布了新的文献求助10
刚刚
1秒前
所所应助小飞采纳,获得30
3秒前
rrt发布了新的文献求助10
4秒前
隐形曼青应助小密母采纳,获得10
5秒前
柳柳柳完成签到,获得积分10
6秒前
6秒前
7秒前
JamesPei应助危机的发卡采纳,获得10
8秒前
zzzz完成签到,获得积分10
9秒前
wjt完成签到,获得积分10
10秒前
fanqie发布了新的文献求助10
11秒前
超级碧曼发布了新的文献求助10
11秒前
nibaba完成签到,获得积分10
13秒前
Guo应助喂喂喂采纳,获得10
13秒前
柳柳柳发布了新的文献求助30
14秒前
16秒前
pengli1981完成签到 ,获得积分10
16秒前
在水一方应助狂野大公猪采纳,获得10
16秒前
17秒前
18秒前
18秒前
20秒前
Pepsi发布了新的文献求助10
21秒前
23秒前
小密母发布了新的文献求助10
23秒前
cy发布了新的文献求助10
25秒前
小傅完成签到,获得积分10
25秒前
小仙女发布了新的文献求助10
25秒前
26秒前
Passion08发布了新的文献求助10
27秒前
大模型应助用户采纳,获得10
28秒前
29秒前
文南犬发布了新的文献求助10
29秒前
科研通AI6.2应助白泽采纳,获得10
30秒前
30秒前
31秒前
Akim应助rrt采纳,获得10
32秒前
miao完成签到 ,获得积分10
32秒前
lzl发布了新的文献求助10
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Organometallic Chemistry of the Transition Metals 800
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
全相对论原子结构与含时波包动力学的理论研究--清华大学 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6439504
求助须知:如何正确求助?哪些是违规求助? 8253414
关于积分的说明 17566657
捐赠科研通 5497644
什么是DOI,文献DOI怎么找? 2899300
邀请新用户注册赠送积分活动 1876115
关于科研通互助平台的介绍 1716638